Real-World Effectiveness and Safety of Upadacitinib in Crohn’s Disease

The real-world effectiveness and safety of upadacitinib in Crohn’s disease were assessed in a multicenter retrospective study involving 9 tertiary inflammatory bowel disease (IBD) centers across North America. This study provided insights into the use of upadacitinib in routine clinical practice, focusing on a large cohort of patients with moderate-to-severe Crohn’s disease who were often refractory to prior treatments. Below is a detailed summary of the findings:

### **Study Overview**

• **Patient Population**: The study included 334 adults with active Crohn’s disease, most of whom had a long disease duration and significant prior exposure to advanced therapies, including biologics or small molecules.
• **Treatment Protocol**: Upadacitinib, an oral JAK1 inhibitor, was administered as 45 mg daily for induction, followed by 30 mg daily for maintenance therapy in the majority of patients.

---

### **Effectiveness Outcomes**

1. **Clinical Remission**:

• **At 12 Weeks**: Over half of the patients achieved clinical remission by the end of the induction period.
• **At 6 Months**: Clinical remission rates were maintained or improved in patients who continued on treatment, demonstrating sustained effectiveness.

2. **Endoscopic Healing**:

• Endoscopic remission, reflecting meaningful mucosal healing, was achieved in more than 40% of evaluated patients at 6 months.

3. **Therapy-Naïve Patients**:

• Patients who were naïve to advanced therapies (biologics or small molecules) had the highest rates of clinical and endoscopic remission, suggesting upadacitinib may be particularly effective in this subgroup.

4. **Refractory Patients**:

• Even in patients with prior exposure to multiple biologics or small molecules, upadacitinib demonstrated effectiveness, underscoring its utility in refractory cases.

5. **Impact of Disease Duration**:

• Longer disease duration was associated with lower odds of achieving remission, indicating that earlier intervention may yield better outcomes.

6. **Predictors of Response**:

• **Negative Predictor**: Higher body mass index (BMI) independently reduced the likelihood of achieving clinical remission.
• **Positive Predictor**: Higher baseline albumin levels were associated with better clinical outcomes.

7. **Disease Location**:

• Short-term remission rates were comparable between patients with ileal-dominant and colon-dominant Crohn’s disease.

8. **Biomarker and Imaging Improvement**:

• Significant reductions in C-reactive protein (CRP) levels were observed, indicating biological anti-inflammatory effects.
• Radiographic imaging showed improvement or resolution of inflammation in the majority of assessed patients.

9. **Histologic Outcomes**:

• Histologic remission was achieved in a smaller subset of patients, reflecting stringent criteria and limited biopsy data.

10. **Steroid-Sparing Effect**:

• Most patients who achieved remission were able to discontinue corticosteroids by follow-up, highlighting the steroid-sparing potential of upadacitinib.

---

### **Safety Profile**

1. **Adverse Events**:

• Adverse events were reported in a minority of patients, and no new safety signals were identified.
• The safety profile was consistent with prior clinical trials.

2. **Serious Adverse Events**:

• Serious adverse events, including venous thromboembolism, were infrequent, suggesting an acceptable safety profile for upadacitinib in this population.

---

### **Clinical Implications**

• **Effectiveness in Real-World Settings**: The study supports upadacitinib as an effective treatment option for moderate-to-severe Crohn’s disease, including in patients with refractory disease or prior treatment failures.
• **Best Results in Therapy-Naïve Patients**: Upadacitinib may offer the greatest benefit when used earlier in the treatment course, particularly in therapy-naïve patients.
• **Personalized Treatment**: Factors such as BMI, albumin levels, and disease duration should be considered when predicting treatment response and tailoring therapy.

---

### **Conclusion**

Upadacitinib demonstrated robust real-world effectiveness and an acceptable safety profile in the treatment of moderate-to-severe Crohn’s disease. It was effective across various patient subgroups, including those with refractory disease, and showed meaningful clinical, endoscopic, and biomarker improvements. These findings support its role as a valuable therapeutic option in managing Crohn’s disease in routine clinical practice.